Pfizer strikes gene therapy deal with Sangamo – PharmaTimes
PharmaTimes |
Pfizer strikes gene therapy deal with Sangamo
PharmaTimes Pfizer and Sangamo are to collaborate on the commercialisation and development of gene therapy programmes for haemophilia A, including SB-525, one of Sangamo's four lead product candidates. Sangamo will receive a $70m upfront payment from Pfizer … Pfizer top hemophilia choice, enters Sangamo pact that is valued to $500M-plus |
